07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Hovione, Invion deal

Invion and Hovione partnered to develop a dry powder formulation of Invion’s asthma candidate INV104 (zafirlukast) delivered using Hovione’s inhaler. Invion is responsible for development and regulatory submissions, and Hovione will manufacture and supply the...
07:00 , Aug 18, 2014 |  BioCentury  |  Strategy

Breathing room

AstraZeneca plc 's acquisition of Almirall S.A. 's respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination...
07:00 , May 16, 2011 |  BC Week In Review  |  Clinical News

Accolate zafirlukast inflammation data

Researchers from the University of Aberdeen reported data from 2 open-label pragmatic trials showing that leukotriene antagonists Singular and Accolate produced equivalent increases in MiniAQLQ scores vs. inhaled corticosteroid controller medication (ICS) as first-line therapy...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Clinical News

Singulair montelukast: Post-marketing study data

Data from a U.S., observational, comparative effectiveness study of integrated medical claims, pharmacy claims and eligibility files of 56,168 asthmatics showed that patients had better overall results with oral leukotriene modifiers than with inhaled corticosteroids...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

Singulair montelukast regulatory update

FDA requested that manufacturers of leukotriene modifying drugs for asthma update the labels of such drugs to include a precaution about behavior and mood changes that have been reported in patients taking the drugs. The...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

Zyflo CR zileuton CR regulatory update

FDA requested that manufacturers of leukotriene modifying drugs for asthma update the labels of such drugs to include a precaution about behavior and mood changes that have been reported in patients taking the drugs. The...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

Zyflo zileuton IR regulatory update

FDA requested that manufacturers of leukotriene modifying drugs for asthma update the labels of such drugs to include a precaution about behavior and mood changes that have been reported in patients taking the drugs. The...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

Accolate zafirlukast regulatory update

FDA requested that manufacturers of leukotriene modifying drugs for asthma update the labels of such drugs to include a precaution about behavior and mood changes that have been reported in patients taking the drugs. The...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Clinical News

Singulair montelukast regulatory update

FDA said a preliminary analysis of data from clinical trials of Merck's Singulair montelukast and other leukotriene modifying drugs for asthma do not suggest the agents are associated with suicide or suicidal behavior, though the...
07:00 , Mar 31, 2008 |  BC Week In Review  |  Clinical News

Accolate zafirlukast regulatory update

FDA said it is reviewing postmarketing reports of behavior and mood changes, suicidality and suicide in Accolate zafirlukast from AstraZeneca and Zyflo zileuton and Zyflo CR from Critical Therapeutics, a pair of leukotriene-modifying drugs for...